For the quarter ending 2026-03-31, PYXS has $64,300K in assets. $33,032K in debts. $5,766K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 5,766 | 15,422 | 8,919 | 10,733 |
| Marketable debt securities | 35,252 | 51,435 | 67,337 | 78,211 |
| Restricted cash | 1,472 | 1,472 | 1,472 | 1,472 |
| Accounts receivable | - | - | - | 3,000 |
| Prepaid expenses and other current assets | 3,082 | 3,776 | 5,345 | 6,540 |
| Total current assets | 45,572 | 72,105 | 83,073 | 99,956 |
| Property and equipment gross | - | 15,004 | - | - |
| Less accumulated depreciation and amortization | - | 7,007 | - | - |
| Property and equipment, net | 7,538 | 7,997 | 8,460 | 8,924 |
| Intangible assets, net | - | 0 | 2,434 | 2,488 |
| Operating lease right-of-use asset | 11,190 | 11,418 | 11,637 | 11,847 |
| Total assets | 64,300 | 91,520 | 105,604 | 123,215 |
| Accounts payable | 4,989 | 10,885 | 9,756 | 9,412 |
| Accrued expenses and other current liabilities | 9,786 | 8,554 | 7,996 | 6,698 |
| Operating lease liabilities, current portion | 1,757 | 1,692 | 1,630 | 1,568 |
| Total current liabilities | 16,532 | 21,131 | 19,382 | 17,678 |
| Operating lease liabilities, net of current portion | 16,497 | 16,958 | 17,400 | 17,832 |
| Financing lease liabilities, net of current portion | 3 | 23 | 43 | 62 |
| Total liabilities | 33,032 | 38,112 | 36,825 | 35,572 |
| Common stock, 0.001 par value per share 190,000,000 shares authorized 62,831,246 and 62,690,229 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively | 63 | 63 | 62 | 62 |
| Additional paid-in capital | 497,654 | 496,469 | 493,719 | 490,654 |
| Accumulated other comprehensive income | 0 | 53 | 69 | -5 |
| Accumulated deficit | -466,449 | -443,177 | -425,071 | -403,068 |
| Total stockholders' equity | 31,268 | 53,408 | 68,779 | 87,643 |
| Total liabilities and stockholders' equity | 64,300 | 91,520 | 105,604 | 123,215 |
Pyxis Oncology, Inc. (PYXS)
Pyxis Oncology, Inc. (PYXS)